Stockscreener 앱 받기
87.84
2.61%
-2.35
시간 외 거래:
87.84
전일 마감가:
$90.19
열려 있는:
$89.66
하루 거래량:
419.92K
Relative Volume:
0.49
시가총액:
$6.02B
수익:
$217.17M
순이익/손실:
$-202.68M
주가수익비율:
-38.14
EPS:
-2.3028
순현금흐름:
$-156.63M
1주 성능:
-2.96%
1개월 성능:
+3.13%
6개월 성능:
-13.66%
1년 성능:
+41.65%
1일 변동 폭
$87.75
$90.90
1주일 범위
$84.90
$92.13
52주 변동 폭
$58.71
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
87.84 | 6.18B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 개시 | RBC Capital Mkts | Outperform |
| 2025-11-25 | 개시 | Citigroup | Buy |
| 2025-11-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-07-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 57% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Rhythm Pharmaceuticals CAO Christopher German sells $428,131 in stock - Investing.com India
Rhythm Pharmaceuticals CAO Christopher German sells $428,131 in stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) officer sells 4,643 shares after exercising options - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM) reports Q1 loss, tops revenue estimates - MSN
Rhythm Pharmaceuticals, Inc. (RYTM): Exploring a 52.67% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Perceptive-affiliated holders report 5.1% stake in Rhythm (RYTM) - Stock Titan
Liquidity Mapping Around (RYTM) Price Events - Stock Traders Daily
Expanded EU IMCIVREE Label for Hypothalamic Obesity Could Be A Game Changer For Rhythm (RYTM) - Sahm
Rhythm Pharmaceuticals, Inc.Common Stock (NQ: RYTM - FinancialContent
Rhythm Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
BofA Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $149 - Moomoo
Green Thumb Just Made an Unprecedented Move. Here's What It Means for GTBIF Investors. - The Motley Fool
RYTM: Strong HO launch, global reach, and next-gen therapies drive growth in rare obesity markets - TradingView
RYTM: Strong HO launch, robust pipeline, and next-gen therapies to address key patient needs - TradingView
HC Wainwright Issues Pessimistic Outlook for RYTM Earnings - MarketBeat
Comerica Bank Cuts Stake in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
New Setmelanotide Data Shapes Rhythm Pharmaceuticals Obesity Growth Story - Sahm
Guggenheim Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $143 - 富途牛牛
Guggenheim Remains a Buy on Rhythm Pharmaceuticals (RYTM) - The Globe and Mail
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology - marketscreener.com
Hidden hunger in rare obesity: new UK study finds severe hyperphagia missed - Stock Titan
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $105 - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Gem with 46.76% Upside Potential - DirectorsTalk Interviews
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approvals And Strong First Quarter Results - Sahm
Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
RYTM Maintained by Canaccord Genuity -- Price Target Raised to $143 - GuruFocus
Rhythm Pharmaceuticals Price Target Raised to $143.00/Share From $140.00 by Canaccord Genuity - Moomoo
Rhythm Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:RYTM) 2026-05-07 - Seeking Alpha
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results - Sahm
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $143 - Moomoo
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2026 Earnings Call Transcript - Insider Monkey
Rhythm Pharmaceuticals (RYTM) Receives a Buy from Guggenheim - The Globe and Mail
Rhythm Pharmaceuticals Q1 2026 Earnings: Stock Rises 8% on Imcivree Revenue BeatNews and Statistics - IndexBox
A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $130 to $144 - Moomoo
Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call - Sahm
Rhythm Pharmaceuticals to Participate in Bank of America Conference on May 13, 2026 - geneonline.com
Morgan Stanley Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $136 - Moomoo
Rhythm Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Rhythm CEO to speak at Bank of America healthcare conference May 13 - Stock Titan
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference - GlobeNewswire
Rhythm Pharmaceuticals Q1 2026 slides: revenue beats on HO launch By Investing.com - Investing.com Australia
MSN Money - MSN
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday - The Motley Fool
Needham Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Rhythm Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Rhythm Pharmaceuticals (RYTM) grows Q1 2026 revenue but posts larger net loss - Stock Titan
Rhythm Pharmaceuticals Weighs Long Term IMCIVREE Data And Growth Potential - Yahoo Finance
Rhythm Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):